{"id":"NCT04207736","sponsor":"Aldeyra Therapeutics, Inc.","briefTitle":"The INVIGORATE Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis.","officialTitle":"The INVIGORATE Trial: A Randomized, Double-masked, Crossover Design, Vehicle-controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of Reproxalap Ophthalmic Solution (0.25%) Compared to Vehicle in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber (EEC)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-12-05","primaryCompletion":"2021-02-16","completion":"2021-02-16","firstPosted":"2019-12-23","resultsPosted":"2024-11-20","lastUpdate":"2024-11-20"},"enrollment":95,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Allergic Conjunctivitis"],"interventions":[{"type":"DRUG","name":"Reproxalap Ophthalmic Solution (0.25%)","otherNames":[]},{"type":"DRUG","name":"Vehicle Ophthalmic Solution","otherNames":[]}],"arms":[{"label":"Reproxalap Ophthalmic Solution (0.25%)","type":"ACTIVE_COMPARATOR"},{"label":"Vehicle Ophthalmic Solution","type":"PLACEBO_COMPARATOR"}],"summary":"The INVIGORATE Trial: A Randomized, Double-masked, Crossover Design, Phase 3 Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis.","primaryOutcome":{"measure":"Subject-Reported Ocular Itching Score Assessed Over 110 to 210 Minutes in the Allergy Chamber","timeFrame":"The efficacy assessment period was 110 to 210 minutes in the allergy chamber; baseline was pre-Dose #1 for each treatment period.","effectByArm":[{"arm":"Reproxalap (0.25%)","deltaMin":0.94,"sd":0.08},{"arm":"Vehicle","deltaMin":1.38,"sd":0.08}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":6},"locations":{"siteCount":1,"countries":["Canada"]},"refs":{"pmids":["38105911"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":91},"commonTop":["General disorders and administrations site conditions","Eye disoders"]}}